Literature DB >> 1312124

Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts.

K Takahashi1, H Okamoto, S Kishimoto, E Munekata, K Tachibana, Y Akahane, H Yoshizawa, S Mishiro.   

Abstract

An ELISA was used to detect a protein derived from the core gene of the hepatitis C virus (HCV) in human plasma. The solid phase antibody in the assay was a murine monoclonal antibody against a synthetic peptide deduced from the putative core gene of HCV (residues 39 to 74). An enzyme-labelled affinity-purified human antibody directed at another region within the HCV core (residues 5 to 23) was the second antibody tracer. The ELISA had a sensitivity capable of detecting a few ng/ml of the HCV core polypeptide expressed in Escherichia coli. Core antigen activity in plasma of infected hosts was detected after treatment of HCV RNA-rich fractions from buoyant density centrifugation with the detergent Tween 80. There was a direct correlation between core antigen ELISA values of a plasma fraction and intensities of polymerase chain reaction signals for HCV RNA. These observations are consistent with the proposal that the N-terminal sequence of the predicted polyprotein of HCV is a nucleocapsid protein, and that improved core antigen assays may correlate with viraemia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312124     DOI: 10.1099/0022-1317-73-3-667

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

Review 1.  Uses of flow cytometry in virology.

Authors:  J J McSharry
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

2.  Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients.

Authors:  P Maillard; K Krawczynski; J Nitkiewicz; C Bronnert; M Sidorkiewicz; P Gounon; J Dubuisson; G Faure; R Crainic; A Budkowska
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen.

Authors:  K Aoyagi; C Ohue; K Iida; T Kimura; E Tanaka; K Kiyosawa; S Yagi
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

4.  Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.

Authors:  Masahiko Takahashi; Hidetsugu Saito; Makiko Higashimoto; Kazuhiro Atsukawa; Hiromasa Ishii
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  Resistant-Associated Substitutions Do Not Affect HCV RNA and HCV Core Antigen Clearance During Direct-Acting Antiviral Agent Treatment in a Real-World Setting.

Authors:  Hongyu Chen; Jianxiang Liu; Qian Kang; Hao Luo; Ning Tan; Jiali Pan; Yuqing Yang; Min Yu; Dan Liu; Hongli Xi; Yifan Han; Ran Cheng; Yanyan Yu; Xiaoyuan Xu
Journal:  Infect Drug Resist       Date:  2022-06-28       Impact factor: 4.177

6.  Synthetic gene for the hepatitis C virus nucleocapsid protein.

Authors:  Y E Khudyakov; H A Fields; M O Favorov; N S Khudyakova; M T Bonafonte; B Holloway
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971

7.  Correlation of serum antibody titers against hepatitis C virus core protein with clinical features by western blot (immunoblot) analysis using a recombinant vaccinia virus expression system.

Authors:  A Nishizono; M Hiraga; K Mifune; H Terao; T Fujioka; M Nasu; T Goto; J Misumi; M Moriyama; Y Arakawa
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

8.  Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes.

Authors:  M Hijikata; Y K Shimizu; H Kato; A Iwamoto; J W Shih; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.